Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: connect (210), relate (736), link (879), correlate (16), bracket together (13), unite (64)

Hospital trust appoints country's first consultant pharmacist in diabetes

Description: Southampton's teaching hospitals have developed a new clinical post which could be rolled out nationally to help improve care for patients
Url: /AboutTheTrust/Newsandpublications/Latestnews/2017/March-2017/Hospital-trust-appoints-countrys-first-consultant-pharmacist-in-diabetes.aspx

CHINA Protocol v2 4.1.11

Description: REC reference 10/H0501/67 1 The CHildren's INterval Appendicectomy (CHINA) Study A Prospective Randomised Evaluation of Interval Appendicectomy versus Conservative
Url: /Media/Southampton-Clinical-Research/Research-protocol/CHINA-Protocol-v2-4.1.11.pdf

Covert treatment

Description: Covert treatment
Url: /HealthProfessionals/Clinical-law-updates/Covert-treatment.aspx

Whipple's procedure - patient information

Description: Your doctors have recommended that you have an operation called the Whipple's procedure. This is a complex operation to remove part
Url: /Media/UHS-website-2019/Patientinformation/Digestionandurinaryhealth/Whipples-procedure-3311-PIL.pdf

University Hospital Southampton NHS Foundation Trust Constitution

Description: Read our constitution here.
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/University-Hospital-Southampton-NHS-Foundation-Trust-Constitution.pdf

Cyclophosphamide Docetaxel Epirubicin (100) Fluorouracil Pertuzumab Trastuzumab FE100CT-HP

Description: Chemotherapy Protocol BREAST CANCER CYCLOPHOSPHAMIDE-DOCETAXEL-EPIRUBICIN (100)- FLUOROURACILPERTUZUMAB-TRASTUZUMAB (FE100CT-HP) Regimen • Breast Cancer – Cyclophosphamide-Docetaxel-Epirubicin (100)-FluorouracilPertuzumab-Trastuzumab
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Cyclophosphamide-Docetaxel-Epirubicin-100-Fluorouracil-Pertuzumab-Trastuzumab-FE100CT-HP.pdf

Finance and Performance Reports 2024-25 Month 5 August 2024

Description: Report to the Trust Board of Directors Title: Agenda item: Sponsor: Author: Date: Purpose: Finance Report 2024-25 Month 5 N/A – No me
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2024-Trust-documents/Finance-and-Performance-Reports-2024-25-Month-5-August-2024.pdf

Institutional information_2022-23_final

Description: Institutional information – key facts for inclusion as appropriate Support statements must be personal to your application
Url: /Media/Southampton-Clinical-Research/Grants/Download/Institutional-information-2022-23-final.pdf

Choosing where to have your baby - patient information

Description: Choosing where to have your baby Contents Introduction 3 Home birth 4 Birth centres 7 New Forest Birth Centre 8 Broadlands
Url: /Media/UHS-website-2019/Patientinformation/Pregnancyandbirth/Choosingwheretohaveyourbaby.pdf

ObinutuzumabVenetoclax LowRisk

Description: Chemotherapy Protocol Chronic Lymphocytic Leukaemia Obinutuzumab-Venetoclax (Low Risk) Regimen • CLL – Obinutuzumab-Venetoclax (Low Risk) Indication • Chronic lymphatic leukaemia (CLL) or
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/ObinutuzumabVenetoclax-LowRisk.pdf

391 to 400 of 647

Previous … 38 39 40 41 42 … Next